Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope
Eli Lilly's shares are near a record high as the company files six lawsuits against alleged illegal sales of its experimental obesity drug, retatrutide. These legal actions aim to protect the drug's future market ahead of its planned U.S. submission in Q1 2027, given its strong Phase 3 efficacy data. The lawsuits are a proactive measure to safeguard its next major franchise, as current revenue drivers Mounjaro and Zepbound already contribute significantly to Lilly's earnings.